" class="no-js "lang="en-US"> Relmada Therapeutics Appoints Fabiana Fedeli to Board
Thursday, May 23, 2024

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

Relmada Therapeutics, a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom’s largest and longest established investment houses, as an independent director to the Company’s Board of Directors.

Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy. In her current role at M&G Investments, which Ms. Fedeli joined in 2021, she leads a team of over 100 investment professionals with assets deployed across the globe. She is responsible for teams managing assets in the UK, US, Singapore, Hong Kong and France. Prior to joining M&G Investments, Ms. Fedeli served as Global Head of Fundamental Equities, Managing Director, at Robeco Asset Management, from 2013-2021. In this role, she led Robeco’s Fundamental Equities investments, with over 70 direct and indirect reports based in Rotterdam, Zurich, Hong Kong and Shanghai, for a total assets under management of $47 billion. Earlier in Ms. Fedeli’s career, she held senior portfolio management and research positions at multiple leading institutional investment firms and investment banks, including Pioneer Investment Management, Occam Asset Management, Indus Capital Partners, Lehman Brothers, and ING Barings Corp.

“Fabiana is a renowned global capital markets expert, and we are delighted to add her to the Board,” stated Charles J. Casamento, Relmada’s Chairman of the Board. “Fabiana’s extensive global business and economic expertise adds important diversity to the Board and will be invaluable to us as we approach potential commercialization of REL-1017. On behalf of the entire Board, we look forward to working closely with Fabiana to further enhance long-term shareholder value.”

“I am thrilled to be joining Relmada’s Board at this exciting time in the Company’s corporate evolution,” said Ms. Fedeli. “I firmly believe that Relmada has many potentially value-creating opportunities ahead, and am eager to work with the rest of the Board and the management team to best leverage these exciting prospects.”

Ms. Fedeli holds advisory and board positions, and regularly speaks at industry events on asset allocation, governance and sustainability. Fabiana is a member of the Investment Committee of The Investment Association, a trade body representing Investment Managers in the UK that collectively manage over US$12 trillion in assets. She is also a member of the Investment Committee of UK-based The Open University, and a non-executive director on the Board of M&G Investments South Africa. In 2022, she was named by Financial News one of 100 Most Influential Women in Finance. She is regularly published in print and interviewed on TV and radio. Ms. Fedeli holds a Master of Economics from Hitosubashi University in Tokyo, Japan, and a Bachelor’s in Economics from Bocconi University in Milan, Italy. She also received a Certificate in Financial Asset Management and Engineering from the University of Lausanne, Swiss France Institute, in Lausanne, Switzerland.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more